Fresh2 Group (Fresh2 Group) FCF Margin % : 0.00% (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Fresh2 Group FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Fresh2 Group's Free Cash Flow for the three months ended in Jun. 2023 was $0.00 Mil. Fresh2 Group's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. Therefore, Fresh2 Group's FCF Margin % for the quarter that ended in Jun. 2023 was 0.00%.

As of today, Fresh2 Group's current FCF Yield % is -57.24%.

The historical rank and industry rank for Fresh2 Group's FCF Margin % or its related term are showing as below:

FRES' s FCF Margin % Range Over the Past 10 Years
Min: -477.36 Med: -423.85 Max: -299.68
Current: -468.9

During the past 6 years, the highest FCF Margin % of Fresh2 Group was -299.68%. The lowest was -477.36%. And the median was -423.85%.

FRES's FCF Margin % is ranked worse than
66.25% of 1034 companies
in the Biotechnology industry
Industry Median: -148.935 vs FRES: -468.90

Fresh2 Group FCF Margin % Historical Data

The historical data trend for Fresh2 Group's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh2 Group FCF Margin % Chart

Fresh2 Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-331.70

-477.36

-299.68

-420.79

-470.25

Fresh2 Group Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23
FCF Margin %	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of Fresh2 Group's FCF Margin %

For the Biotechnology subindustry, Fresh2 Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fresh2 Group's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fresh2 Group's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Fresh2 Group's FCF Margin % falls into.

Fresh2 Group FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Fresh2 Group's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-8.126	/	1.728
	=	-470.25 %

Fresh2 Group's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	0	/	0
	=	%

Fresh2 Group FCF Margin % Related Terms

Thank you for viewing the detailed overview of Fresh2 Group's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Fresh2 Group (Fresh2 Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh2 Group Ltd (NAS:FRES) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

0UC0:Germany

Address

650 5TH Avenue, Street 2416, NEW YORK, NY, USA, 10019-6108

Website

https://www.fresh2.co

Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.